logo
logo

Nucleai Closes $33 Million Series B Financing To Advance Spatial Biology Platform For Drug Research, Development And Diagnostics

Mar 22, 2022over 3 years ago

Amount Raised

$33 Million

Round Type

series b

Tel Aviv

Description

Nucleai, an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, today announced that it had closed a $33 million Series B financing round, jointly led by Section 32 and Sanofi Ventures. Andy Harrison, Managing Partner at Section 32, and Cris De Luca, Global Head, Digital Investments at Sanofi Ventures, will join Nucleai’s Board of Directors. Section 32 Managing Partner Michael Pellini, MD, will join Nucleai’s Board as an observer. Nucleai plans to use the new funding to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations (CROs), who are applying its technology throughout translational research, clinical trials, and novel applications for drug discovery.

Company Information

Company

Nucleai

Location

Tel Aviv, Tel Aviv District, Israel

About

Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making. For more information, please visit www.nucleai.ai.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech